2417821-30-6
Chemical Structure
p-SCN-Macropa
- CAS No.: 2417821-30-6
- Formula:C35H43N5O9S
- Molecular Weight:709.81
InChIKey: QHYGURIGHVXBBI-UHFFFAOYSA-N
SMILES: OC(C1=NC(CN2CCOCCOCCN(CC3=NC(C(O)=O)=CC=C3)CCOCCOCC2)=CC(OCCC4=CC=C(N=C=S)C=C4)=C1)=O
Biological Activity: p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonal antibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for 225Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
p-SCN-Macropa | 96.46% | p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonal antibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for 225Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Tikum AF, et al. Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models. J Nucl Med. Published online February 15, 2024. [Content Brief]
- [2]. Pougoue Ketchemen J, et al. Highly potent [225Ac]Ac-macropa-trastuzumab-PEG6-DM1 antibody drug radioconjugate against HER2-positive breast cancer xenografts. J Nucl Med. 2024;65(suppl 2):242451.
- [3]. Vallabhajosula S, et al. SCN-PYTA: A new bifunctional chelator (BFC) for trivalent radiometals to develop target-specific radiopharmaceuticals for imaging and therapy. Cancer Res. 2026;86(7 Suppl):Abstract 7183.
